EA201790403A1 - ANTIBODIES AGAINST LAG3 AND ANTIGEN-BINDING FRAGMENTS - Google Patents

ANTIBODIES AGAINST LAG3 AND ANTIGEN-BINDING FRAGMENTS

Info

Publication number
EA201790403A1
EA201790403A1 EA201790403A EA201790403A EA201790403A1 EA 201790403 A1 EA201790403 A1 EA 201790403A1 EA 201790403 A EA201790403 A EA 201790403A EA 201790403 A EA201790403 A EA 201790403A EA 201790403 A1 EA201790403 A1 EA 201790403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
fragments
antigen
binding fragments
antibodies against
Prior art date
Application number
EA201790403A
Other languages
Russian (ru)
Other versions
EA039293B1 (en
Inventor
Линда Лян
Лоренс Фаядат-Дилман
Рене Де Вааль Мейлфит
Гопалан Рагхунатхан
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Priority claimed from PCT/US2015/045481 external-priority patent/WO2016028672A1/en
Publication of EA201790403A1 publication Critical patent/EA201790403A1/en
Publication of EA039293B1 publication Critical patent/EA039293B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Abstract

Настоящее изобретение относится к антителам и их антигенсвязывающим фрагментам, которые специфически связываются с LAG3 человека или яванского макака, а также к их иммуноглобулиновым цепям и полинуклеотидам, кодирующим их, и к инъецирующим устройствам, содержащим такие антитела или фрагменты. Изобретение включает вакцины, включающие такие антитела и фрагменты, а также композиции, содержащие антитела и фрагменты (например, включающие антитела против PD1). Также предусматриваются способы лечения или предупреждения злокачественной опухоли или инфекции с использованием таких композиций. Кроме того, способы рекомбинантной экспрессии антител и фрагментов являются частью настоящего изобретения.The present invention relates to antibodies and their antigen-binding fragments that specifically bind to human or cynomolgus LAG3, as well as their immunoglobulin chains and polynucleotides encoding them, and to injecting devices containing such antibodies or fragments. The invention includes vaccines comprising such antibodies and fragments, as well as compositions containing antibodies and fragments (for example, comprising antibodies against PD1). Methods of treating or preventing a malignant tumor or infection using such compositions are also contemplated. In addition, methods for recombinant expression of antibodies and fragments are part of the present invention.

EA201790403A 2015-06-05 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments EA039293B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171319P 2015-06-05 2015-06-05
PCT/US2015/045481 WO2016028672A1 (en) 2014-08-19 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments

Publications (2)

Publication Number Publication Date
EA201790403A1 true EA201790403A1 (en) 2017-06-30
EA039293B1 EA039293B1 (en) 2021-12-30

Family

ID=80632887

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790403A EA039293B1 (en) 2015-06-05 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments

Country Status (1)

Country Link
EA (1) EA039293B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596871A4 (en) * 2003-02-28 2006-08-23 Drew M Pardoll T cell regulation
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AR072999A1 (en) * 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
UY34887A (en) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES

Also Published As

Publication number Publication date
EA039293B1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CY1124252T1 (en) ANTI-LAG3 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS
MX2018007406A (en) Anti-lag3 antibodies and antigen-binding fragments.
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201992038A1 (en) ANTI-PSF-TAU-ANTIBODIES AND WAYS OF THEIR APPLICATION
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
EA201791171A1 (en) ANTIBODIES TO TIGIT
EA202191380A1 (en) ANTIBODIES TO ALPHA-SYNUCLEINE AND THEIR APPLICATION
EA201991720A1 (en) ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
EA201791270A1 (en) MODIFIED APRIL-BINDING ANTIBODIES
EA201991546A1 (en) ANTIGEN-BINDING PROTEINS AGAINST NEUROPILIN AND WAYS OF THEIR APPLICATION
MX2015016978A (en) Cmv neutralizing antigen binding proteins.
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
EA201691521A1 (en) ANTIBODIES TO INTERLEUKIN-21
EA201890434A1 (en) ANTIBODIES TO CD154 AND METHODS OF THEIR APPLICATION
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
EA201990895A1 (en) ANTIBODIES TO O1 AND OPTIONS OF THEIR APPLICATION
EA201691095A1 (en) OSPA MUTANT FRAGMENTS AND RELATED METHODS AND APPLICATIONS
EA201990222A1 (en) ANTIBODIES TO O2 AND WAYS OF THEIR APPLICATION
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
EA201790336A1 (en) ANTIBODIES TO ANGIOPOETHIN-LIKE PROTEIN 4 AND METHODS OF APPLICATION
EA201990988A1 (en) ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
EA201790403A1 (en) ANTIBODIES AGAINST LAG3 AND ANTIGEN-BINDING FRAGMENTS
EA202193035A1 (en) MATERIALS AND METHODS FOR T-CELL-MEDIATED IMMUNE MODULATION